Recent News Releases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared Melbourne, Australia, and Basel, Switzerland – Oct 5, 2026 – CSL...

KING OF PRUSSIA, Pa., September 29, 2026 | CSL today announced a collaboration with Amazon Web Services (AWS) to apply artificial intelligence and cloud technologies to support the company’s...

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, UK | 10 September...

Agreements support lower prices for CSL therapies and reflect CSL's $1.5 billion plan to expand its U.S. manufacturing capacity in Illinois KING OF PRUSSIA, Pa., - August 31, 2026 – CSL...

Dear ANCA‑associated vasculitis community, Further to our last update regarding TAVNEOS® (avacopan), we wanted to inform you that the European Commission (EC) has adopted a decision revoking...

ST. GALLEN, SWITZERLAND – 6 August, 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Commission (EC) has adopted the decision revoking the...

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress

Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, SWITZERLAND – 26 June 2026 Vifor...